Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections

PROVECTUS BIOPHARMACEUTICALS, INC.

VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.
Seed round term sheet (non-binding) for up to $3M in three tranches at valuations tied to Series A; 5,278 Class B shares issued.
University of Miami (Bascom Palmer) receives minority equity; 5% ownership until $2M qualified investment.
Initial directors: Webster Bailey, Jack Lacey, Ed Pershing (Chair). Officers: Dominic Rodrigues (Acting CEO), Heather Raines (Acting CFO).
RB PDAT tested in >500 patients globally; targeting $60B ophthalmic market with broad-spectrum antimicrobial therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.